Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of
November 7, 2017


Actelion Pharmaceuticals Ltd /
Cancellation of publicly held Actelion shares and delisting from SIX Swiss 
Exchange as of November 7, 2017 
. Verarbeitet und übermittelt durch Nasdaq Corporate Solutions.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Source: Globenewswire

ALLSCHWIL/BASEL,  SWITZERLAND - October 31, 2017 - By decision dated October 25,
2017, the  Cantonal  Court  of  the  Canton  of  Basel-Landschaft  cancelled all
publicly  held registered shares of Actelion Ltd (Actelion) with a nominal value
of  CHF 0.50 each (the Actelion Shares) based  on article 137 of the Federal Act
on  Financial  Market  Infrastructures  and  Market  Conduct  in  Securities and
Derivatives Trading (Financial Market Infrastructure Act).

The holders of the cancelled Actelion Shares will be paid a cash compensation in
the  amount of USD 280  for each cancelled  Actelion Share, corresponding to the
offer  price paid by Janssen  Holding GmbH, an indirect  subsidiary of Johnson &
Johnson,  in its public tender offer for  all publicly held Actelion Shares. The
settlement   and   payment   of  the  compensation  to  the  remaining  minority
shareholders of Actelion will take place on or around November 10, 2017.

By decision dated April 18, 2017, SIX Exchange Regulation approved the delisting
of  the Actelion Shares  from SIX Swiss  Exchange. By decision dated October 30,
2017, SIX  Exchange Regulation  determined that  the last  day of trading of the
Actelion  Shares will be  November 6, 2017 and that  the Actelion Shares will be
delisted from SIX Swiss Exchange on November 7, 2017.

                                      ###

NOTES TO EDITORS

About Johnson & Johnson

Caring  for the world, one  person at a time,  inspires and unites the people of
Johnson  & Johnson. We embrace research and science - bringing innovative ideas,
products  and  services  to  advance  the  health  and well-being of people. Our
approximately  130,800 employees at  more than  250 Johnson &  Johnson operating
companies work with partners in health care to touch the lives of over a billion
people every day, throughout the world.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At  the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to
create  a world  without disease.  Transforming lives  by finding new and better
ways  to  prevent,  intercept,  treat  and  cure  disease  inspires us. We bring
together  the best minds and pursue the  most promising science. We are Janssen.
We  collaborate with the world  for the health of  everyone in it. Learn more at
www.janssen.com.      Follow     us     at     www.twitter.com/JanssenUS     and
www.twitter.com/JanssenGlobal.

About Actelion Ltd

In  June 2017, Actelion became  part of the  Janssen Pharmaceutical Companies of
Johnson  & Johnson.  Actelion's medicines  help expand  and strengthen Janssen's
portfolio  with leading, differentiated in-market  medicines and promising late-
stage  compounds. Janssen has added Pulmonary Hypertension as a therapeutic area
of  focus  to  maintain  the  leadership  position  Actelion  has  built in this
important disease area.

For further information please contact:
Investor Relations - Actelion Pharmaceuticals Ltd
+41 61 565 6565
www.actelion.com


NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This  press  release  contains  "forward-looking  statements"  as defined in the
Private  Securities Litigation Reform  Act of 1995 regarding  the acquisition of
Actelion  Ltd.  The  reader  is  cautioned  not to rely on these forward-looking
statements. These statements are based on current expectations of future events.
If  underlying  assumptions  prove  inaccurate  or  known  or  unknown  risks or
uncertainties  materialize,  actual  results  could  vary  materially  from  the
expectations  and  projections  of  Johnson  &  Johnson. Risks and uncertainties
include,  but are not limited to: risks and uncertainties related to the ability
of  the  Johnson  &  Johnson  family  of companies to successfully integrate the
products,  employees/operations and  clinical work  of Actelion,  as well as the
ability to ensure continued performance or market growth of Actelion's products;
the  potential that the  expected benefits and  opportunities of the transaction
may  not be  realized or  may take  longer to  realize than expected; challenges
inherent  in  product  research  and  development,  including the uncertainty of
clinical  success and obtaining regulatory  approvals; uncertainty of commercial
success  for  new  and  existing  products; competition, including technological
advances,  new products and patents  attained by competitors; adverse litigation
or  government action;  challenges to  patents; changes  to applicable  laws and
regulations,  including  domestic  and  foreign  health care reforms; changes in
behavior  and spending  patterns or  financial distress  of purchasers of health
care  products  and  services;  manufacturing  difficulties  and delays; product
efficacy  or safety concerns resulting in  product recalls or regulatory action;
and  trends toward health care cost  containment. A further list and description
of these risks, uncertainties and other factors and the general risks associated
with the respective businesses of Johnson & Johnson and Actelion can be found in
Johnson  & Johnson's  publicly available  filings with  the U.S.  Securities and
Exchange  Commission, and Actelion's publicly  available filings on its website.
Copies  of these filings, as well as subsequent filings, are available online at
www.sec.gov, www.jnj.com, www.actelion.com or on request from Johnson & Johnson.
Johnson  & Johnson does not undertake to update any forward-looking statement as
a result of new information or future events or developments.

Medienmitteilung PDF: 
http://hugin.info/131801/R/2145790/822635.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate
Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content,
accuracy and originality of the information contained therein.
    
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire

http://www.actelion.com